Equities research analysts expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to report earnings per share of $0.18 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Meridian Bioscience’s earnings. The highest EPS estimate is $0.19 and the lowest is $0.17. Meridian Bioscience reported earnings of $0.15 per share during the same quarter last year, which indicates a positive year over year growth rate of 20%. The business is scheduled to issue its next earnings report on Thursday, January 24th.

On average, analysts expect that Meridian Bioscience will report full-year earnings of $0.76 per share for the current financial year, with EPS estimates ranging from $0.74 to $0.81. For the next year, analysts anticipate that the business will report earnings of $0.80 per share, with EPS estimates ranging from $0.77 to $0.83. Zacks’ EPS calculations are an average based on a survey of analysts that cover Meridian Bioscience.

Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings data on Thursday, November 8th. The company reported $0.20 EPS for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.04. Meridian Bioscience had a net margin of 11.49% and a return on equity of 16.97%. The firm had revenue of $213.60 million for the quarter, compared to the consensus estimate of $51.11 million. During the same period in the previous year, the firm posted $0.15 earnings per share. The firm’s revenue was up 6.4% on a year-over-year basis.

VIVO has been the topic of a number of research analyst reports. ValuEngine raised shares of Meridian Bioscience from a “hold” rating to a “buy” rating in a research report on Monday, October 29th. BidaskClub raised shares of Meridian Bioscience from a “hold” rating to a “buy” rating in a research report on Wednesday, October 24th. Finally, Zacks Investment Research raised shares of Meridian Bioscience from a “hold” rating to a “strong-buy” rating and set a $23.00 price objective on the stock in a research report on Saturday. One investment analyst has rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $19.50.

VIVO traded up $0.09 on Friday, reaching $19.72. 434,428 shares of the company traded hands, compared to its average volume of 290,581. Meridian Bioscience has a 52-week low of $13.53 and a 52-week high of $19.84. The company has a market capitalization of $719.87 million, a PE ratio of 26.65 and a beta of 0.54. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.89 and a current ratio of 5.73.

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 30th. Shareholders of record on Monday, November 19th will be given a $0.125 dividend. This represents a $0.50 annualized dividend and a yield of 2.54%. The ex-dividend date of this dividend is Friday, November 16th. Meridian Bioscience’s dividend payout ratio is 67.57%.

In other Meridian Bioscience news, Director John Mcilwraith bought 2,000 shares of the firm’s stock in a transaction on Friday, August 24th. The stock was bought at an average cost of $15.63 per share, with a total value of $31,260.00. Following the completion of the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $93,780. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 2.70% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC grew its position in Meridian Bioscience by 9.1% in the second quarter. Renaissance Technologies LLC now owns 2,631,276 shares of the company’s stock worth $41,837,000 after acquiring an additional 220,500 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Meridian Bioscience by 0.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,828,334 shares of the company’s stock worth $29,071,000 after acquiring an additional 9,714 shares in the last quarter. Systematic Financial Management LP grew its position in Meridian Bioscience by 11.3% in the second quarter. Systematic Financial Management LP now owns 1,131,715 shares of the company’s stock worth $17,994,000 after acquiring an additional 114,687 shares in the last quarter. SG Americas Securities LLC grew its position in Meridian Bioscience by 60.0% in the second quarter. SG Americas Securities LLC now owns 11,742 shares of the company’s stock worth $187,000 after acquiring an additional 4,404 shares in the last quarter. Finally, BlackRock Inc. grew its position in Meridian Bioscience by 9.6% in the second quarter. BlackRock Inc. now owns 5,901,032 shares of the company’s stock worth $93,827,000 after acquiring an additional 518,731 shares in the last quarter. 88.56% of the stock is owned by institutional investors.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

See Also: S&P 500 Index

Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.